查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球臨床試驗市場 - 2023-2030
市場調查報告書
商品編碼
1279674

全球臨床試驗市場 - 2023-2030

Global Clinical Trials Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 195 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概覽

全球臨床試驗市場預計將實現利潤豐厚的增長，到 2022 年將達到 566.407 億美元，到 2030 年將達到 992.12 億美元。 在預測期內（2023-2030 年），臨床試驗市場預計將以 7.4% 的複合年增長率增長。

臨床試驗是一種臨床調查程序，由經過仔細驗證的指定協議監督，以解決詳細的患者護理查詢。 臨床試驗分為五個階段，每個階段都有特定的臨床試驗目的。 所有臨床試驗均受制於定義誰可以參與試驗的系統。 研發支出的增加、對新療法的需求不斷增加以及不斷變化的監管指南正在推動預測期內全球臨床試驗市場的增長。

市場動態

合同研究組織 (CROS) 的興起預計將在預測期內推動臨床試驗市場的增長

每年，製藥行業都會生產各種具有顯著醫療效益的新藥。 藥物發現是一個昂貴且不確定的過程，許多潛在的藥物從未進入市場。 因此，公司將這些任務外包給 CRO 以降低成本。 CRO 為製藥和生物技術公司提供藥物研究外包服務。

CRO 根據所有標準和法規要求管理和完成圖像處理過程，以實現順利的圖像採集、分析、註釋和傳輸。 近年來，CRO 服務在開發新藥和治療的早期階段協助公司。 製藥公司越來越多地使用臨床研究、諮詢和實驗室 CRO 服務。

臨床研究資金的增加正在推動全球臨床試驗市場的增長

未來幾年，預計來自各個主管部門的資金增加將為全球臨床試驗市場提供有利可圖的增長機會。 例如，2023年1月，作為加拿大生物製造和生命科學戰略（BLSS）的一部分，加拿大衛生研究院（CIHR）的臨床試驗基金（CTF）啟動了中風研究、行為改變、生物統計學和臨床研究。我們計劃接受超過 3200 萬加元的共同投資，以向新一代研究人員和研究人員傳授我們的專業知識，包括我們已知的方法。

COVID-19 影響分析

對 COVID-19 的分析包括 COVID 之前、COVID 和 COVID 之後的情景、價格動態（與 COVID 之前的情景相比，大流行期間和之後的價格變動）、供需範圍（由於供應和需求的變化還解釋了貿易限制、封鎖和後續問題）、政府舉措（政府機構為振興市場、部門和行業而採取的舉措）、製造商的戰略舉措（製造商為緩解 COVID 問題所做的努力）。

俄烏戰爭影響分析

烏克蘭和俄羅斯都是國際臨床試驗活動的廣泛基地。 對烏克蘭的攻擊可能會破壞國際臨床試驗的結果，因為這兩個國家有前途的招募中心都失敗了。 軍事衝突造成的中斷對醫療保健產生了重大影響，包括臨床試驗和癌症護理。

全球經濟衰退影響分析

一些專家擔心，隨著經濟持續放緩，許多國家正處於衰退的邊緣。 公司正在密切關注其影響，但生物製藥領域尤為關注。 經濟衰退將不可避免地迫使一些公司改變他們的方法。 但一些生物技術公司可能會受到更健康的結果的影響。 預計生物技術公司將尋求技術來填補資金缺口，從而提高效率、更快獲得結果並改變生物技術研究人員的工作方式。

人工智能影響分析

人工智能對臨床試驗市場產生積極影響。 通過採用 AI 支持的技術，研究人員可以從過去和最近的研究中獲得見解，探索大量數據，並報告對未來研究設計的任何必要調整。 在進一步的臨床試驗中，人工智能在診斷和治療疾病方面也有很大的應用潛力。

內容

第一章調查方法及範圍

  • 調查方法
  • 調查目的和範圍

第 2 章定義和概述

第 3 章執行摘要

  • 特定階段的片段
  • 設計的片段
  • 按視圖摘錄
  • 按服務分類的片段
  • 區域摘要

第四章市場動態

  • 影響因素
    • 主持人
      • 研發費用增加
      • 有利的監管準則
    • 約束因素
      • 成本高，成功概率低
    • 機會
    • 政府舉措
    • 影響分析

第五章行業分析

  • 波特的五力分析
  • 害蟲分析
  • 監管分析
  • 價格分析

第 6 章 COVID-19 分析

  • COVID-19 分析
    • COVID-19 之前的情景
    • 當前的 COVID-19 情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格和動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 結論

第七章俄烏戰爭分析

第八章全球經濟衰退分析

第9章人工智能的影響分析

第 10 章階段

  • 第三階段
  • 第二階段
  • 第一階段
  • 第四階段

第 11 章的設計

  • 治療研究
    • 隨機對照試驗
      • 雙盲隨機研究
      • 單盲隨機研究
      • 非盲隨機試驗
    • 適應性臨床試驗
    • 非隨機對照試驗
  • 觀察研究
    • 潛在隊列
      • 回顧性隊列
      • 時間序列隊列
    • 病例對照研究
    • 隊列研究
    • 橫斷面研究
    • 生態研究

第12章適應症

  • 腫瘤科
  • 免疫疾病
  • 糖尿病
  • 感染
  • 其他

第 13 章服務

  • 實驗室服務
  • 醫療器械測試服務
  • 臨床試驗數據管理服務
  • 生物分析測試服務
  • 其他

第14章按地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第15章競爭格局

  • 競爭場景
  • 市場份額分析
  • 併購分析

第十六章公司簡介

  • Iqvia Holdings Inc.（Q2 解決方案）
    • 公司簡介
    • 階段組合和描述
    • 財務摘要
    • 主要發展狀況
  • Parexel International Corporation
  • Charles River Laboratories International, Inc.
  • Syneos Health, Inc.
  • WuXi AppTec Co., Ltd.（WuXi Clinical）
  • ICON plc
  • Thermo Fisher Scientific（Pharmaceutical Product Development LLC）
  • Azelix
  • Pharmaron Beijing Co., Ltd.
  • Celerion

第17章 附錄

簡介目錄
Product Code: PH244

Market Overview

The global clinical trials market reached USD 56,640.7 million in 2022 and is projected to witness lucrative growth by reaching up to USD 99,212.0 million by 2030. The clinical trials market is expected to exhibit a CAGR of 7.4% during the forecast period (2023-2030).

Clinical trials are a methodology of clinical investigation that is overseen by a designated protocol that is carefully verified to respond to a detailed patient care query. Clinical trials are bifurcated into five phases, with every phase carrying a specific intent within the clinical trial. Every trial confers to a system that defines what sorts of people may partake in the study. The increasing R&D spending, growing need for new therapeutics, and evolving regulatory guidelines are driving the global clinical trials market growth during the forecast period.

Market Dynamics

The Rising Number of Contract Research Organizations (CROS) is Expected to Drive the Clinical Trials Market Growth During the Forecast Period.

Every year, the pharmaceutical industry creates a variety of new drugs that provide significant medical advantages. Developing new medicines is a costly and uncertain process, and many potential drugs never make it to market as a result, in order to save money, companies outsource these tasks to CROs. CROs provide pharmaceutical and biotechnology industries with outsourced pharmaceutical research services.

The CROs manage and complete the imaging process in accordance with all standards and regulatory requirements, ensuring smooth image acquisition, analysis, annotation, and transfer. In recent years, CRO services have helped companies in the early stages of developing novel medicines and therapies. Pharmaceutical firms are increasingly using clinical research, consultancy, and laboratory CRO services.

The Increasing Funding for Clinical Research is Driving the Global Clinical Trials Market Growth.

The growing funding from various authorities is expected to provide the global clinical trials market with lucrative growth opportunities in the upcoming years. For instance, in January 2023, as part of Canada's Biomanufacturing and Life Sciences Strategy (BLSS), the Canadian Institutes of Health Research (CIHR) Clinical Trials Fund (CTF) is expected to be accepting a joint investment of more than CAD 32 M to instruct a fresh generation of researchers and investigators in expertise as stroke research, behavioral change, biostatistics, and the known approach of clinical research.

COVID-19 Impact Analysis

The COVID-19 analysis includes Pre-COVID Scenario, COVID Scenario, and Post-COVID Scenario along with pricing dynamics (including pricing change during and post-pandemic comparing it to pre-COVID scenarios), demand-supply spectrum (shift in demand and supply owing to trading restrictions, lockdown, and subsequent issues), government initiatives (initiatives to revive market, sector or industry by government bodies) and manufacturers strategic initiatives (what manufacturers did to mitigate the COVID issues will be covered here).

Russia-Ukraine War Impact Analysis

Ukraine and Russia are both extensive bases for international clinical trial activity. The attack on Ukraine may cause an underpowering of global clinical trial outcomes with the failure of prospective recruitment locations for both nations. The turmoil and disorder induced by military confrontation have a significant influence over healthcare including clinical trials and cancer care.

Global Recession Impact Analysis

As the economic slump persists, multiple specialists are concerned that many countries are on the cusp of a recession. While every enterprise is overseeing the possible fallout, those in the biopharma domain may be especially anxious regarding the outcomes. The recession is expected inevitably cause multiple firms to alter their approach. Nonetheless, it could influence a few biotechs for sounder outcomes. It is anticipated that biotechs' will look towards technology to compensate for funding shortcuts, that are expected to result in improved efficiencies, quicker results, and a shift in the way biotech researchers work.

Artificial Intelligence Impact Analysis

Artificial intelligence has a positive impact on the clinical trials market as employing AI-enabled technologies, the investigators can analyze and yield understanding from prior and recent trials, research huge data, and report the needed adjustment in prospective trial designs. In further clinical trials, AI has a tremendous possibility in the diagnosis of disorders and treatment applications as well.

Segment Analysis

The global clinical trials market is segmented based on phase, design, indication, service, and region.

The Phase III Segment is Estimated to Hold a 47.6% Share of the Global Market by 2030.

The phase III segment is estimated to hold about 47.1% of the global clinical trials market by 2030. For instance, in May 2022, the last patient is projected to begin treatment in June 2022, according to Lipidor AB (publ), which reports that half of the patients have already been enrolled in the Phase III research of the AKP02 skin spray for mild to moderate psoriasis. In the third quarter of 2022, top-line results from the Phase III investigation are anticipated.

In December 2022, by showing a statistically significant decrease in HbA1c (a measure of average blood sugar) with Jardiance (empagliflozin) compared with placebo for children and adolescents aged 10-17 years with type 2 diabetes, the DINAMO phase III clinical trial fulfilled its primary aim.

Geographical Analysis

Europe is Estimated to Hold the Second-largest Share of the Global Clinical Trials Market During the Forecast Period.

The increasing government initiatives for research drive the market in the European region and are estimated to hold around 27.7% of the total global market by 2030. For instance, in January 2022, the European Commission (EC), the Heads of Medicines Agencies, and the European Medicines Agency introduced an initiative to transform how clinical trials are initiated, developed, and run, directed to Accelerating Clinical Trials in the EU (ACT EU).

The goal is to further expand the EU as a focal point for clinical research, advance the development of high-quality, safe, and effective medicines, and better incorporate clinical research in the European health system. Creating the application of the Clinical Trials Regulation and the takeoff of the Clinical Trials Information Systems in January 2022, ACT EU will support the European environment for clinical trials while maintaining data robustness, a high level of protection of trial participants, and the transparency that EU citizens expect.

Competitive Landscape

The major global players in the market include: Iqvia Holdings Inc. (Q2 Solutions), Parexel International Corporation, Charles River Laboratories International, Inc., Syneos Health, Inc., WuXi AppTec Co., Ltd. (WuXi Clinical), ICON plc, Thermo Fisher Scientific (Pharmaceutical Product Development LLC), Azelix, Pharmaron Beijing Co., Ltd., and Celerion among others.

Why Purchase the Report?

  • To visualize the global clinical trials market segmentation based on product, application, and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of clinical trials market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The global clinical trials market report would provide approximately 53 tables, 54 figures, and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Phase
  • 3.2. Snippet by Design
  • 3.3. Snippet by Indication
  • 3.4. Snippet by Service
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing R&D Spending.
      • 4.1.1.2. Favorable Regulatory Guidelines.
    • 4.1.2. Restraints
      • 4.1.2.1. High Cost and Low Success Probability.
    • 4.1.3. Opportunity
    • 4.1.4. Government Initiatives
    • 4.1.5. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. PEST Analysis
  • 5.3. Regulatory Analysis
  • 5.4. Pricing Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Before COVID-19 Scenario
    • 6.1.2. Present COVID-19 Scenario
    • 6.1.3. Post COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturers' Strategic Initiatives
  • 6.6. Conclusion

7. Russia-Ukraine War Analysis

8. Global Recession Analysis

9. Artificial Intelligence Impact Analysis

10. By Phase

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Phase
    • 10.1.2. Market Attractiveness Index, By Phase
  • 10.2. Phase III
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Phase II
  • 10.4. Phase I
  • 10.5. Phase IV

11. By Design

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Design
    • 11.1.2. Market Attractiveness Index, By Design
  • 11.2. Treatment Studies*
    • 11.2.1. Introduction
    • 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 11.2.3. Randomized Control Trial
      • 11.2.3.1. Double-Blind Randomized Trial
      • 11.2.3.2. Single Blind Randomized Trial
      • 11.2.3.3. Non-Blind Randomized Trial
    • 11.2.4. Adaptive Clinical Trial
    • 11.2.5. Non-Randomized Control Trial
  • 11.3. Observational Studies
    • 11.3.1. Prospective Cohort
      • 11.3.1.1. Retrospective Cohort
      • 11.3.1.2. Time Series Cohort
    • 11.3.2. Case-Control Study
    • 11.3.3. Cohort Study
    • 11.3.4. Cross-Sectional Study
    • 11.3.5. Ecological Study

12. By Indication

  • 12.1. Introduction
    • 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 12.1.2. Market Attractiveness Index, By Indication
  • 12.2. Oncology
    • 12.2.1. Introduction
    • 12.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 12.3. Immunological Diseases
  • 12.4. Diabetes
  • 12.5. Infectious diseases
  • 12.6. Others

13. By Services

  • 13.1. Introduction
    • 13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Services
    • 13.1.2. Market Attractiveness Index, By Services
  • 13.2. Laboratory Services
    • 13.2.1. Introduction
    • 13.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 13.3. Medical Device Testing Services
  • 13.4. Clinical Trial Data Management Services
  • 13.5. Bioanalytical Testing Services
  • 13.6. Others

14. By Region

  • 14.1. Introduction
    • 14.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 14.1.2. Market Attractiveness Index, By Region
  • 14.2. North America
    • 14.2.1. Introduction
    • 14.2.2. Key Region-Specific Dynamics
    • 14.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Phase
    • 14.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Design
    • 14.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 14.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Services
    • 14.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 14.2.7.1. The U.S.
      • 14.2.7.2. Canada
      • 14.2.7.3. Mexico
  • 14.3. Europe
    • 14.3.1. Introduction
    • 14.3.2. Key Region-Specific Dynamics
    • 14.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Phase
    • 14.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Design
    • 14.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 14.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Services
    • 14.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 14.3.7.1. Germany
      • 14.3.7.2. The U.K.
      • 14.3.7.3. France
      • 14.3.7.4. Italy
      • 14.3.7.5. Spain
      • 14.3.7.6. Rest of Europe
  • 14.4. South America
    • 14.4.1. Introduction
    • 14.4.2. Key Region-Specific Dynamics
    • 14.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Phase
    • 14.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Design
    • 14.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 14.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Services
    • 14.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 14.4.7.1. Brazil
      • 14.4.7.2. Argentina
      • 14.4.7.3. Rest of South America
  • 14.5. Asia-Pacific
    • 14.5.1. Introduction
    • 14.5.2. Key Region-Specific Dynamics
    • 14.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Phase
    • 14.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Design
    • 14.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 14.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Services
    • 14.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 14.5.7.1. China
      • 14.5.7.2. India
      • 14.5.7.3. Japan
      • 14.5.7.4. Australia
      • 14.5.7.5. Rest of Asia-Pacific
  • 14.6. Middle East and Africa
    • 14.6.1. Introduction
    • 14.6.2. Key Region-Specific Dynamics
    • 14.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Phase
    • 14.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Design
    • 14.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 14.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Services

15. Competitive Landscape

  • 15.1. Competitive Scenario
  • 15.2. Market Share Analysis
  • 15.3. Mergers and Acquisitions Analysis

16. Company Profiles

  • 16.1. Iqvia Holdings Inc. (Q2 Solutions)
    • 16.1.1. Company Overview
    • 16.1.2. Phase Portfolio and Description
    • 16.1.3. Financial Overview
    • 16.1.4. Key Developments
  • 16.2. Parexel International Corporation
  • 16.3. Charles River Laboratories International, Inc.
  • 16.4. Syneos Health, Inc.
  • 16.5. WuXi AppTec Co., Ltd. (WuXi Clinical)
  • 16.6. ICON plc
  • 16.7. Thermo Fisher Scientific (Pharmaceutical Product Development LLC)
  • 16.8. Azelix
  • 16.9. Pharmaron Beijing Co., Ltd.
  • 16.10. Celerion

LIST NOT EXHAUSTIVE

17. Appendix

  • 17.1. About Us and Services
  • 17.2. Contact Us